BeOne Medicines price target raised to $416 from $413 at Truist
Truist raised the firm's price target on BeOne Medicines to $416 from $413 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises wit